Zydus Lifesciences Balance Sheet Health
Financial Health criteria checks 6/6
Zydus Lifesciences has a total shareholder equity of ₹241.5B and total debt of ₹1.5B, which brings its debt-to-equity ratio to 0.6%. Its total assets and total liabilities are ₹314.5B and ₹72.9B respectively. Zydus Lifesciences's EBIT is ₹53.8B making its interest coverage ratio -100.4. It has cash and short-term investments of ₹25.0B.
Key information
0.6%
Debt to equity ratio
₹1.50b
Debt
| Interest coverage ratio | -100.4x |
| Cash | ₹24.95b |
| Equity | ₹241.55b |
| Total liabilities | ₹72.91b |
| Total assets | ₹314.46b |
Recent financial health updates
These 4 Measures Indicate That Zydus Lifesciences (NSE:ZYDUSLIFE) Is Using Debt Safely
Nov 30
Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Jun 10Recent updates
Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Might Deserve Your Attention Today
Dec 16These 4 Measures Indicate That Zydus Lifesciences (NSE:ZYDUSLIFE) Is Using Debt Safely
Nov 30Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Just Reported Earnings, And Analysts Cut Their Target Price
Nov 15Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching
Sep 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market
Aug 30Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 03Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jul 19Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 05Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jun 20Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Jun 10Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
May 25Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?
Mar 18Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%
Feb 28Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report
Feb 12Financial Position Analysis
Short Term Liabilities: ZYDUSLIFE's short term assets (₹121.6B) exceed its short term liabilities (₹53.5B).
Long Term Liabilities: ZYDUSLIFE's short term assets (₹121.6B) exceed its long term liabilities (₹19.4B).
Debt to Equity History and Analysis
Debt Level: ZYDUSLIFE has more cash than its total debt.
Reducing Debt: ZYDUSLIFE's debt to equity ratio has reduced from 61.1% to 0.6% over the past 5 years.
Debt Coverage: ZYDUSLIFE's debt is well covered by operating cash flow (3062.5%).
Interest Coverage: ZYDUSLIFE earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 21:53 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zydus Lifesciences Limited is covered by 69 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Bhasin | Ambit Capital |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |